Markets:

Overview

News

Currencies

International

Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

579.89 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗

March 19, 2024

Madrigal has one key advantage over its two huge potential future rivals.

Via The Motley Fool

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2024

Via Benzinga

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗

March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Via The Motley Fool

Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 3/15 Morning Trading

March 15, 2024

Via Investor Brand Network

Madrigal Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2024

Via Benzinga

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 15, 2024

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates.

Via Benzinga

FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring ↗

March 15, 2024

FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease....

Via Benzinga

Why Is Geron (GERN) Stock Up 94% Today? ↗

March 15, 2024

Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing.

Via InvestorPlace

Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday ↗

March 15, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported...

Via Benzinga

Topics Stocks

MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today ↗

March 15, 2024

Madrigal Pharmaceuticals stock is up on Friday as MDGL investors celebrate FDA approval of NASH treatment Rezdiffra today.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 15, 2024

Via Benzinga

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗

March 15, 2024

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 15, 2024

It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 14, 2024

Via Benzinga

Why Madrigal Stock, Which Has Gained 62% In A Month, Just Slumped Ahead Of A Potential First-Ever In MASH ↗

March 14, 2024

The company hopes to be the first to the finish line with a treatment for MASH.

Via Investor's Business Daily

Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. ↗

March 09, 2024

Good news could be in store for all three of these drugmakers.

Via The Motley Fool

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Via Benzinga

1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247? ↗

March 05, 2024

This business could be on the cusp of making medical history.

Via The Motley Fool

Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗

February 26, 2024

The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.

Via Investor's Business Daily

1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street ↗

February 23, 2024

The company might have a bright future, but is now the right time to buy shares?

Via The Motley Fool

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug ↗

February 08, 2024

The company is looking to take on Eli Lilly's tirzepatide as both a shot and a pill for weight loss.

Via Investor's Business Daily

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗

February 06, 2024

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 06, 2024

Via Benzinga

2 Rising Biotechs That Could Become the Next Novo Nordisk ↗

January 29, 2024

Each of these companies has a big market in its sights.

Via The Motley Fool

2 Stocks That Could Soar This Year: Are They Buys? ↗

January 22, 2024

They might perform well in 2024, but how will they do beyond that?

Via The Motley Fool

Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development ↗

January 12, 2024

89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties.

Via Benzinga

3 Stocks That Could Be Monster Winners in 2024 ↗

December 30, 2023

Don't be surprised if these three stocks take off in the new year.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today